Paniagua, Juan ABahamondes, RodrigoCano-Sánchez, AntonioVelasco, Francisco2025-01-072025-01-072017-07-042050-0904https://hdl.handle.net/10668/26641In young patients with T1D, neurological manifestations of cerebral hypertension should suggest the possibility of a cerebral venous sinus thrombosis (CVST). In these patients an inherited prothrombotic risk factor, including factor V Leiden G1691A gene mutation, should be considered during an event of thrombosis. Improving the glycemic control is the first factor that should be controlled in a patient who carries a genetic prothrombotic risk factor. Anticoagulant treatment should be started as son as CVST has been diagnosed. Long-term antithrombotic treatment with tinzaparin 175 IU/kg/day, a low-molecular weight heparin (LMWH), could be reliable and well tolerated, although an indefinite special follow-up, including neurological controls, is advisable even in asymptomatic patients.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Cerebral venous sinus thrombosisinherited thrombophilialow‐molecular weight heparin treatmentpapilledematype 1 diabetesresearch article28781853open access10.1002/ccr3.1067PMC5538076https://doi.org/10.1002/ccr3.1067https://pmc.ncbi.nlm.nih.gov/articles/PMC5538076/pdf